Extranodal NK/T-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Extranodal NK/T-cell lymphoma is a rare form of non-Hodgkin lymphoma that is strongly linked to the Epstein-Barr virus (EBV). The most common cause of this so-called "lethal midline granuloma" manifests almost exclusively in non-nodal sites, most commonly as stage IE/IIE disease in the nose, nasopharynx, oropharynx, and upper aerodigestive tract. Other skin and gastrointestinal tract sites can be involved in more advanced stages. Lymph nodes may have secondary involvement but are generally not the disease's primary site. Given the typical anatomic sites of involvement, the majority of patients present with nasal obstruction or epistaxis; some present with destructive masses involving the nose, sinuses, or palate. Approximately 3% of patients with ENKTL present with hemophagocytic lymphohistiocytosis syndrome characterised by high fevers, cytopenia, abnormal liver function tests, and high ferritin levels due to pathologic immune activation. The typical immunophenotype of ENKTL is similar to that of an NK cell: CD45(+bright), CD2(+), surface CD3(−), cytoplasmic CD3 epsilon(+), CD56(+bright), CD16(−/+), T-cell receptor (TCR) (−), and cytotoxic granule molecules such as granzyme B, TIA-1, and perforin(+). CD30 is variably expressed, often in larger malignant cells, leading to misdiagnosing anaplastic large cell lymphoma. The prognosis for ENKTL varies, but it is especially poor for patients with high-risk disease, as described by the prognostic index for natural killer cell lymphoma (PINK-E).

·       The incidence of Extranodal NK/T-cell lymphoma is low in the United States and Europe, ranging between 0.25% to 0.5% of all newly diagnosed non-Hodgkin lymphomas.

Thelansis’s “Extranodal NK/T-cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Extranodal NK/T-cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Extranodal NK/T-cell Lymphoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Extranodal NK/T-cell Lymphoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Extranodal NK/T-cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033